Mar 14 |
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
|
Mar 8 |
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
|
Mar 1 |
Nuvation Bio GAAP EPS of -$0.06
|
Feb 29 |
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 27 |
12 Best Medical Stocks to Buy Under $10
|
Feb 17 |
Owning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),
|
Jan 8 |
FDA clears Nuvation to begin Phase 1/2 study for oncology drug
|
Jan 8 |
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
|
Jan 8 |
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
|
Dec 4 |
Companies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In Growth
|